MaxCyte Webinars

1. Mitigate Clinical Risk In Cell Therapy Development With A GMP Compliant Process 4/21/2025

   Help shape the future of medicine by building better, safer cell therapies. See how expertise in scalable, GMP-compliant cell engineering can effectively mitigate clinical development risks.

2. High Efficiency Cell Engineering From Concept To Clinic 4/21/2025

   Discover how highly efficient and scalable methods for engineering cells are accelerating the development and delivery of next-generation cell-based treatments for patients.

3. Emerging Manufacturing Technologies For Cell Therapies | Audience Q&A 4/15/2025

   Cell & Gene Live’s Audience Q&A always draws valuable questions in real time from our audience. Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio provide detailed responses to audience questions that addressed the importance of vein-to-vein time for non-cancer indications, such as autoimmune diseases.

4. The Impact Of Cell Therapy Manufacturing On Patient Access And Experience 4/15/2025

   During this segment of Cell & Gene Live, expert panelists, Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio share why improvements in cell therapy manufacturing directly impact the patient experience.

5. Implementing Emerging Manufacturing Technologies For Cell Therapies 4/15/2025

   In this segment of Cell & Gene Live, Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio emphasize the importance of focusing on solving the problem at hand when adopting new technologies.

6. Emerging Technologies In Cell Therapy Manufacturing: Embracing Automation, Robotics, And AI 4/15/2025

   In this segment of our Cell & Gene Live, expert panelists Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio define innovation as benefiting patients and emphasize automation and robotics as central to the cause.

7. Cell Therapy's Current Manufacturing Challenges 4/15/2025

   In this segment, Cell & Gene’s Chief Editor, Erin Harris, welcomes the audience and introduces the expert panelists, Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio.

8. Epitope Base Editing CD45 In Hematopoietic Cells Enables Universal Blood Cancer Immune Therapy 11/22/2024

   Researchers developed base-edited CAR T cells and CD45-edited stem cells to create universal blood cancer immunotherapy, showcasing efficacy while minimizing toxicity using MaxCyte electroporation technology.

9. Unlocking The Potential Of Electroporation 11/22/2024

   Electroporation enables genetic research by introducing material into cells, advancing disease modeling, gene therapy, and ion channel studies. MaxCyte technology offers scalable, efficient solutions for high-throughput applications.

10. Overcome The Limitations Of Conventional Transfection With Electroporation 11/22/2024

    Learn how electroporation technology improves gene editing efficiency, reduces cell death, and enables scalable workflows for cell therapy, screening, and bioproduction in this informative webinar.